2026-04-17T03:00:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/663802025-12-05T09:21:35Zcom_2072_1057col_2072_478799col_2072_478917

00925njm 22002777a 4500 dc Chen, Fred K. author McLenachan, Samuel author Edel, Michael John author Da Cruz, Lyndon author Coffey, Peter J. author Mackey, David A. author 2015-07-16T08:28:21Z 2015-07-16T08:28:21Z 2014-12-19 2015-07-16T08:28:21Z For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration. Cèl·lules mare Malalties de la retina Degeneració (Patologia) Genètica molecular Trasplantament d'òrgans Stem cells Retinal diseases Degeneration (Pathology) Molecular genetics Transplantation of organs iPS Cells for Modelling and Treatment of Retinal Diseases